Medroxyprogesterone Acetate
Product Images NDC 52125-915

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Medroxyprogesterone Acetate (NDC 52125-915). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for medroxyprogesterone acetate 150 mg/mL injection for intramuscular use. The label indicates quantity 1, NDC 52125-0915-01, manufactured by Greenstone LLC, Peapack, NJ, and repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions specify 20-25°C with permitted excursions. The label includes a QR code and a reference number 59762-4538-02.*

FDA Label Image

Figure 1 (Medroxyprogesterone 01)

A logarithmic scale odds ratio forest plot with 95% confidence intervals from multiple studies (1987 to 2012) showing risk estimates related to DMPA use. The graph includes study names, odds ratio points with horizontal lines indicating confidence intervals, a vertical reference line at 1.0, and annotations for odds ratio values with their intervals. The x-axis represents odds ratios ranging approximately from 0.6 to 7.4.*

FDA Label Image

Chemical Structure (Medroxyprogesterone 02)

Chemical structure diagram of medroxyprogesterone acetate showing its steroid backbone with associated functional groups including ketones and acetoxy groups.*

FDA Label Image

Logo (Medroxyprogesterone 03)

FDA Label Image

Figure (Medroxyprogesterone 04)

A vertical arrow chart illustrating pregnancy rates per 100 women per year, arranged from fewer pregnancies at the top to more pregnancies at the bottom. It categorizes birth control methods by effectiveness: top methods (implants, injections, intrauterine devices, sterilization) correspond to fewer than 1 pregnancy per 100 women, mid-level methods (birth control pills, skin patch, vaginal ring) have slightly more pregnancies, barrier methods (condoms, diaphragm) follow, and less effective methods (no sex during fertile days, spermicide, withdrawal) precede no birth control, associated with 85 or more pregnancies per 100 women per year.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.